Skip to main content
OpenTrials
Completed

NCT Number: NCT07433127

Inflammation Indıces and Mortality in Adult Crush Syndrome

This retrospective observational cohort study aims to evaluate the prognostic value of inflammatory hematological indices, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), systemic inflammatory response index (SIRI), and pan-immune-inflammation value (PIV), in predicting 28-day mortality in adult patients with crush syndrome admitted to the intensive care unit (ICU).

Patients aged 18 years and older diagnosed with crush syndrome between January 1, 2018, and September 30, 2025, were included. The primary outcome is 28-day mortality. Secondary outcomes include ICU mortality and in-hospital mortality. The predictive performance of inflammatory indices will be compared with established severity scores such as APACHE II and SOFA.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Crush Syndrome Critical Illness Crush Injuries Disease Attributes Muscular Diseases Musculoskeletal Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Rhabdomyolysis Shock, Traumatic Systemic Inflammatory Response Wounds and Injuries

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Ataturk University Research Hospital

Erzurum, 20100, Turkey (Türkiye)

About this study

Crush syndrome is a life-threatening condition characterized by severe muscle injury, systemic inflammatory response, acute kidney injury, and high mortality, particularly in disaster-related mass trauma settings. Early risk stratification is crucial for optimizing intensive care management and resource allocation.

This retrospective cohort study includes adult patients (≥18 years) diagnosed with crush syndrome and admitted to the intensive care unit of Ataturk University Hospital between January 1, 2018, and September 30, 2025. Demographic data, laboratory parameters, and clinical severity scores were obtained from electronic medical records.

Inflammatory indices calculated from complete blood count parameters include:

  • Neutrophil-to-lymphocyte ratio (NLR)
  • Platelet-to-lymphocyte ratio (PLR)
  • Monocyte-to-lymphocyte ratio (MLR)
  • Systemic immune-inflammation index (SII)
  • Systemic inflammatory response index (SIRI)
  • Pan-immune-inflammation value (PIV)

The primary endpoint is 28-day mortality following ICU admission. Secondary endpoints include ICU mortality and in-hospital mortality. Multivariate logistic regression and receiver operating characteristic (ROC) curve analyses will be performed to assess the independent prognostic value of inflammatory indices compared with established scoring systems such as APACHE II and SOFA.

The study aims to determine whether readily available hematological indices provide additional prognostic value in critically ill patients with crush syndrome.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years
  • Diagnosis of crush syndrome based on clinical and laboratory findings
  • Admission to the intensive care unit (ICU) between January 1, 2018 and September 30, 2025
  • Availability of complete blood count parameters within the first 24 hours of ICU admission

Exclusion criteria

  • Age <18 years
  • Incomplete medical records
  • Missing laboratory data required for calculation of inflammatory indices
  • Patients discharged or transferred within 24 hours of ICU admission

Treatment and study plan

Primary outcomes

  1. 28-day All-Cause Mortality

    Time frame: 28 Days

    All-cause mortality occurring within 28 days after intensive care unit (ICU) admission in adult patients diagnosed with crush syndrome.

Secondary outcomes

  1. ICU Mortality

    Time frame: During ICU stay (up to 28 days)

    Death occurring during the intensive care unit stay.

  2. In-Hospital Mortality

    Time frame: During hospital stay (up to 90 days)

    All-cause mortality occurring during the index hospital admission.

Sponsors and collaborators

Lead sponsor

Ataturk University

Other

Registry information

Official study title

The Association of Systemic Inflammation-Based Hematological Indices With APACHE II, SOFA and 28-Day Mortality in Adult Crush Syndrome: A Retrospective Cohort Study

Important dates

Study start
2018
Primary completion
2025
Study completion
2025
First posted
Feb 25, 2026
Registry last updated
Feb 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.